547 related articles for article (PubMed ID: 26042933)
1. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.
Beije N; Kraan J; Taal W; van der Holt B; Oosterkamp HM; Walenkamp AM; Beerepoot L; Hanse M; van Linde ME; Otten A; Vernhout RM; de Vos FY; Gratama JW; Sleijfer S; van den Bent MJ
Br J Cancer; 2015 Jul; 113(2):226-31. PubMed ID: 26042933
[TBL] [Abstract][Full Text] [Related]
2. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
3. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
4. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
Rahman R; Hempfling K; Norden AD; Reardon DA; Nayak L; Rinne ML; Beroukhim R; Doherty L; Ruland S; Rai A; Rifenburg J; LaFrankie D; Alexander BM; Huang RY; Wen PY; Lee EQ
Neuro Oncol; 2014 Nov; 16(11):1523-9. PubMed ID: 24958095
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan.
Cuppini L; Calleri A; Bruzzone MG; Prodi E; Anghileri E; Pellegatta S; Mancuso P; Porrati P; Di Stefano AL; Ceroni M; Bertolini F; Finocchiaro G; Eoli M
PLoS One; 2013; 8(9):e74345. PubMed ID: 24069296
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 2D (RANO) and volumetric methods for assessment of recurrent glioblastoma treated with bevacizumab-a report from the BELOB trial.
Gahrmann R; van den Bent M; van der Holt B; Vernhout RM; Taal W; Vos M; de Groot JC; Beerepoot LV; Buter J; Flach ZH; Hanse M; Jasperse B; Smits M
Neuro Oncol; 2017 Jun; 19(6):853-861. PubMed ID: 28204639
[TBL] [Abstract][Full Text] [Related]
7. Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
[TBL] [Abstract][Full Text] [Related]
8. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
10. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Tonder M; Eisele G; Weiss T; Hofer S; Seystahl K; Valavanis A; Stupp R; Weller M; Roth P
Acta Oncol; 2014 Oct; 53(10):1436-40. PubMed ID: 24862539
[No Abstract] [Full Text] [Related]
11. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
12. Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial.
Erdem-Eraslan L; van den Bent MJ; Hoogstrate Y; Naz-Khan H; Stubbs A; van der Spek P; Böttcher R; Gao Y; de Wit M; Taal W; Oosterkamp HM; Walenkamp A; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; van der Holt B; Vernhout RM; Sillevis Smitt PA; Kros JM; French PJ
Cancer Res; 2016 Feb; 76(3):525-34. PubMed ID: 26762204
[TBL] [Abstract][Full Text] [Related]
13. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
14. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
[TBL] [Abstract][Full Text] [Related]
15. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab alone at 5 mg/kg in an every-3-week schedule for patients with recurrent glioblastomas: a single center experience.
Kaloshi G; Brace G; Rroji A; Bushati T; Roci E; Hoxha M; Fejzo G; Petrela M
Tumori; 2013; 99(5):601-3. PubMed ID: 24362864
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Batchelor TT; Mulholland P; Neyns B; Nabors LB; Campone M; Wick A; Mason W; Mikkelsen T; Phuphanich S; Ashby LS; Degroot J; Gattamaneni R; Cher L; Rosenthal M; Payer F; Jürgensmeier JM; Jain RK; Sorensen AG; Xu J; Liu Q; van den Bent M
J Clin Oncol; 2013 Sep; 31(26):3212-8. PubMed ID: 23940216
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.
Weathers SP; Han X; Liu DD; Conrad CA; Gilbert MR; Loghin ME; O'Brien BJ; Penas-Prado M; Puduvalli VK; Tremont-Lukats I; Colen RR; Yung WKA; de Groot JF
J Neurooncol; 2016 Sep; 129(3):487-494. PubMed ID: 27406589
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
20. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
Bertaut A; Truntzer C; Madkouri R; Kaderbhai CG; Derangère V; Vincent J; Chauffert B; Aubriot-Lorton MH; Farah W; Mourier KL; Boidot R; Ghiringhelli F
Oncotarget; 2016 Oct; 7(43):70948-70958. PubMed ID: 27487142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]